Semaglutide effects: the benefits, the side effects, and who should be careful.

The short version

This page covers the human side of semaglutide effects: what people say it does for them, and what the published safety record shows. Two layers, kept separate.

The first layer is what users report — quieter appetite, fewer cravings, weight coming off, steadier blood sugar. These are real experiences but they are stories, not measured trial results, so treat them as anecdote. The second layer is the cited safety record: the stomach side effects that lead people to stop, a boxed warning about a rare thyroid cancer, gallbladder risk, an eye-disease caution, muscle-loss and weight-regain caveats, and warnings about compounded versions.

No dose belongs on this page, and nothing here is a recommendation. It is a plain-English account so a reader has honest context before reading the trials in detail.

What people report

These are effects reported by the patient and research-use community — anecdotal, not clinical evidence, and not verified by controlled trials. They line up broadly with the trial data below, but they are stories, not measurements, and no doses are attached.

Benefits people describe most often

• A quieter relationship with food. By far the most common report is that the constant background chatter about food goes quiet, often within the first week or two. People say they feel full faster, eat a third to a half of their old portions, and stop thinking about the next meal. Many call this the single most life-changing effect. Frequently reported.
• Cravings drop. Sweet-tooth and sugar cravings fade or disappear, and fried, greasy, high-fat foods stop appealing — sometimes turning slightly off-putting. Several people say they naturally drift toward fruit, vegetables and lighter meals. Frequently reported.
• Weight comes off. The large majority of reviewers report losing weight, often describing it as steady and substantial over several months, with the pace slowing after the early period. Many tie it directly to eating much less. Frequently reported.
• Better blood-sugar numbers. Among people using it for type 2 diabetes, a common theme is markedly improved blood-sugar and A1C readings, with morning fasting numbers and long-term averages dropping into normal ranges, and steadier daytime energy. Commonly reported.
• Less interest in alcohol. A recurring secondary observation is that the urge to drink fades along with food cravings, with some people simply losing interest in drinking. Occasionally reported.

Downsides people describe most often

• Nausea, sometimes vomiting. Nausea is the single most reported side effect, mentioned by roughly a third of reviewers, with a subset escalating to vomiting at its worst. It tends to peak in the first weeks and after each dose increase, then ease within a week or two, and it flares after overeating or fatty food. Frequently reported.
• Sulfur or "egg" burps. A distinctive complaint is foul-smelling burps compared to rotten eggs or sulfur, often after a dose increase, sometimes with bloating and a sense of food sitting too long. People say they show up far more than official lists suggest. Commonly reported.
• Bowel changes. Both constipation and diarrhea are reported, sometimes alternating — hard, infrequent stools on one end, and looser stools (worse right after a dose or rich food) on the other. Commonly reported.
• Reflux and heartburn. Indigestion, heartburn and reflux come up, often alongside burping and bloating and tracking with dose increases. Occasionally reported.
• Early fatigue. Tiredness and low energy come up, especially in the day or two after an injection and in the early weeks, usually easing with time. Commonly reported.
• Food aversions and over-suppressed appetite. Beyond eating less, some describe active aversions to fatty or meaty food, a metallic taste, and a heightened, unpleasant sensitivity to smells — likened to morning sickness. For a few, appetite is suppressed so far they must remind themselves to eat. Occasionally reported.
• Hair shedding and a gaunter face. A smaller group reports increased hair shedding a few months in, plus a thinner, more hollow face — both widely attributed to losing weight quickly rather than the drug, with the shedding usually described as temporary. Sometimes reported.
• Headaches and dizziness. Often in the first days of a new dose and frequently linked to not drinking enough or eating too little; many say hydration helps. Occasionally reported.
• Injection-site reactions. Mild redness, itching, a small bump or tenderness where people inject, generally minor and short-lived. Sometimes reported.

Safety and cautions

This is the cited safety record. Where a caution is a measured trial finding, it says so; where it is a precaution or a mechanism-based extrapolation, it says that too.

Semaglutide side effects: GI intolerance, worst during titration. Nausea, vomiting, diarrhea and constipation are the dominant adverse effects in clinical trials and the leading reason people stop. In a pooled analysis of the STEP weight-management program these events were mostly mild-to-moderate and transient, concentrated around the dose-escalation period ^[9]; a dedicated safety review reported nausea in roughly one-third of patients ^[5], and real-world pharmacovigilance reporting is likewise dominated by GI events ^[10]. This is clinical, not theoretical — the slowing of gastric emptying behind the GI effects is part of how the drug works.

Boxed thyroid warning (medullary thyroid carcinoma / MEN-2). GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors, derived from rodent studies in which such tumors occurred at very high exposures ^[7]. A dedicated assessment of thyroid cancer risk concluded that human data do not establish a clear increase attributable to semaglutide, so the human signal is best described as unconfirmed ^[5]; even so, a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is treated as a contraindication on the strength of the rodent finding.

Acute pancreatitis (class warning). Acute pancreatitis is a recognized class warning, and treatment is conventionally stopped if pancreatitis is suspected. The same safety review notes that pancreatic-cancer signals remain ones for which firm conclusions cannot yet be drawn, owing to low incidence rather than a confirmed association ^[5]. The caution is precautionary, not a demonstrated quantitative risk increase.

Gallbladder and biliary disease. A dedicated safety review found an increased risk of biliary disease, such as gallstones, with semaglutide, attributed largely to the rate and magnitude of weight loss rather than direct drug toxicity ^[5]. The increase versus placebo is a real trial and pharmacovigilance finding, not merely theoretical.

Pre-existing diabetic retinopathy with rapid glucose lowering. In SUSTAIN-6, diabetic-retinopathy complications were significantly more frequent with semaglutide (HR 1.76; 95% CI 1.11-2.78), concentrated among people who already had eye disease and whose HbA1c fell quickly ^[2]. The leading interpretation is early worsening driven by the speed of correction rather than direct retinal toxicity; monitoring is advised when glucose is corrected rapidly ^[5]. This is a trial signal in people with diabetes.

Loss of lean (muscle) mass. A STEP-program body-composition substudy reported that the weight lost comprised both fat and a meaningful proportion of lean mass ^[16]. Because rapid, large weight loss can erode muscle, this raises a sarcopenia (muscle-wasting) concern, especially in older adults, and has motivated research into protein intake and resistance training. The lean-mass loss is observed; the downstream sarcopenia risk is a reasoned extrapolation.

Weight regain after stopping. Stopping is followed by substantial weight regain. In the STEP 1 trial extension, participants regained a mean of roughly 11.6 percentage points of body weight within a year of stopping, and cardiometabolic improvements drifted back toward baseline ^[17]; the STEP 4 randomized-withdrawal design likewise showed regain after switching to placebo ^[18]. This frames obesity drug therapy as ongoing rather than a one-time cure.

Hair shedding with rapid weight loss. A pharmacovigilance analysis identified a reporting signal for alopecia (hair loss) with semaglutide and tirzepatide ^[15], and a separate dermatology study linked telogen effluvium — a reversible, diffuse shedding — to the magnitude and rate of weight loss ^[19]. The signal is most consistent with rapid-weight-loss shedding rather than direct drug toxicity.

Pregnancy: contraindicated, with a long washout. Semaglutide is contraindicated in pregnancy per the approved labeling. Because its half-life is about a week, with effectively complete clearance only about five weeks after the last dose, label guidance advises stopping well in advance of a planned pregnancy — commonly cited as roughly two months ^[14]. The half-life arithmetic is documented; the contraindication itself is a regulatory statement.

Oral form must be taken fasted. Oral semaglutide is co-formulated with an absorption enhancer called SNAC and has very low oral bioavailability (about 0.4-1%), so it must be taken on an empty stomach with only a little water and kept apart from other food, drink and oral medicines ^[20][14]. Administration errors can substantially cut the absorbed dose, and therefore the effect. This is a formulation requirement, not a toxicity.

Narrow-margin oral drugs during titration. A systematic review of interactions between GLP-1 receptor agonists and oral medicines found that the delayed gastric emptying generally does not cause clinically significant interactions, but advised caution and monitoring for narrow-therapeutic-index drugs, especially during dose escalation ^[21]. The overall interaction risk is characterized as low; the caution is targeted and monitoring-based.

Then and now

Semaglutide is the product of decades of incretin-peptide chemistry, built on an earlier GLP-1 analogue and engineered for once-weekly dosing through DPP-4 resistance and albumin binding ^[14]. It first reached FDA approval for type 2 diabetes in 2017, with an oral once-daily tablet following in 2019-2020 and a chronic weight-management approval in 2021 ^[1]. Its cardiovascular-outcomes evidence (SELECT) read out in 2023 ^[3] and its kidney-outcomes evidence (FLOW) in 2024 ^[6], with a fatty-liver (MASH) indication following in 2025 ^[13]. During a federally declared shortage from roughly 2022 to early 2025, compounding pharmacies were permitted to produce semaglutide; that pathway was curtailed once the shortage was declared resolved in early 2025 ^[3].